Twenty corporate-action entries are queued on the October calendar, and the pace picks up Monday, when six names consolidate their shares at the open. The headline numbers are extreme: AMTD IDEA Group is collapsing its ADSs 60-to-1, Solowin is doing 200-to-1 on a company worth roughly a quarter of a billion dollars at last check, and Revelation Biosciences is making its sixth reverse split in under four years. This guide covers the upcoming reverse stock splits from October 19 through October 30, with the exact ratios and effective dates, what each company has said, and the price levels that matter after the split. A reverse split changes the share count, not the value of a company, so the real question each time is what comes next.
Upcoming Reverse Stock Splits: Market Snapshot Before the Calendar Opens
| Metric | Latest Verified Close (Thursday, Oct. 15) |
|---|---|
| S&P 500 | 7,744.06 (+0.33%) |
| Dow Jones Industrial Average | 52,177.69 (+1.08%) |
| Nasdaq Composite | 26,713.03 (+0.08%) |
| Russell 2000 | 2,767.27 (+1.38%) |
| VIX | ~16.0 |
| 10-Year Treasury Yield | ~5.10% |
The Russell 2000 gained 1.38% on October 15 while the Nasdaq barely moved, and the 10-year yield, now near 5.10%, touched a 24-year high above 5.36% earlier this month. Friday’s closing figures were not confirmed at press time.
Data note: Split ratios, effective dates and share counts come from company filings and press releases. Prices are the latest we could verify, each labeled with its date, and several are stale or unavailable, which is stated plainly in each table. “Post-split equivalent” is the pre-split price multiplied by the ratio, a theoretical figure only. RSI and MACD are omitted where feeds were stale. Support and resistance levels are analytical zones built from verified prices, 52-week extremes, listing thresholds and round numbers, not targets.
Reverse Stock Split Calendar: October 19–30, 2026
| Effective Date | Ticker | Company | Type | Ratio |
|---|---|---|---|---|
| Oct 19 | AMTD | AMTD IDEA Group | Reverse | 1 for 60 |
| Oct 19 | GP | GreenPower Motor Company | Reverse | 1 for 5 |
| Oct 19 | FRGT | Freight Technologies | Reverse | 1 for 10 |
| Oct 19 | CAPS | Capstone Holding Corp. | Reverse | 1 for 30 |
| Oct 19 | OBAI | Our Bond, Inc. | Reverse | 1 for 20 |
| Oct 19 | INNI | Innovaro | Reverse | 1 for 200 |
| Oct 20 | MBRX | Moleculin Biotech | Reverse | 1 for 20 |
| Oct 20 | REVB | Revelation Biosciences | Reverse | 1 for 7 |
| Oct 22 | BSNLF | Blue Star Helium Limited | Reverse | 1 for 50 |
| Oct 23 | LU | Lufax Holding | Reverse (ADS) | 1 for 10 |
| Oct 23 | HCAI | Huachen AI Parking Management Technology | Reverse | 1 for 20 |
| Oct 26 | AXG | Solowin Holdings | Reverse | 1 for 200 |
| Oct 26 | BDRX | Biodexa Pharmaceuticals | Reverse (ADS) | 1 for 8 |
| Oct 26 | CHOW | ChowChow Cloud International | Reverse | 1 for 10 |
| Oct 26 | AZTR | Azitra Inc | Reverse | 1 for 10 |
| Oct 28 | ENHA | Enhanced Group | Reverse | 1 for 10 |
| Oct 28 | HVNVY | Havas N.V. (unsponsored ADR) | Listed as forward | 0.10 for 1 |
| Oct 29 | OMEX | Odyssey Marine Exploration | Reverse | 1 for 25 |
| Oct 30 | SCAG | Scage Future Ads | Reverse | 1 for 15 |
| Oct 30 | NYSX | Global X NYSE 100 ETF | Listed as forward | 0.20 for 1 |
The calendar tags HVNVY and NYSX as forward splits, but ratios of 0.10-for-1 and 0.20-for-1 normally describe consolidations, so confirm the direction with the issuer or fund sponsor. Many entries are ADS ratio changes, which work like a reverse split for holders without changing the underlying ordinary shares. Ten names get full profiles below, chosen for the most newsworthy and best-documented stories on the list.
1. AMTD IDEA Group (AMTD) | Last Close $0.4979 (-12.26%) | The 1-for-60 ADS Collapse Hits Monday
From Under 40 Cents to Roughly $23: NYSE Compliance Is the Goal
AMTD IDEA changes each ADS from six to 360 Class A shares on or about October 19, a one-for-60 reverse ADS split, to regain compliance with NYSE listing standards.
| Metric | Value |
|---|---|
| Split Terms | 1-for-60 ADS ratio change (6 → 360 Class A shares per ADS); effective ~Oct 19 |
| Last Close (Oct 13) | $0.383 (-8.22%); prior close $0.4173 |
| After-Hours (Oct 13) | $0.459 (+19.8%) |
| Day’s Range / 52-Week Range | $0.3809 – $0.3985 / $0.3809 – $1.65 |
| Market Cap | ~$30.7M |
| Post-Split Equivalent | ~$22.98 ($0.383 × 60) |
| Volume vs. Average | 42,449 vs. ~41,700 average |
| Buyback | 4.42M ADSs repurchased as of Oct. 7 |
| Support 1 / 2 / 3 (pre-split) | $0.3809 / $0.35 / $0.30 → ~$22.85 / $21.00 / $18.00 post-split |
| Resistance 1 / 2 / 3 (pre-split) | $0.4173 / $0.459 / $0.50 → ~$25.04 / $27.54 / $30.00 post-split |
Catalyst & Latest News: Yahoo’s quote page shows the stock closing at a 52-week low before the split, and the company has said the ratio change should help it regain NYSE compliance. This is AMTD’s second ADS consolidation: the first was a one-for-three change in November 2023.
Technicals: The stock closed just above its 52-week low of $0.3809 on October 13, so most pre-split resistance sits above the price.
Fundamentals: The company runs a diversified mix of capital-markets, media, hospitality and strategic-investment businesses.
Bull Case: A single-digit-million-dollar float gets a tradeable price, and buybacks shrink supply. Bear Case: Sixty-to-one splits often fade, and a prior 2023 consolidation did not stop the slide.
What to Watch:
- Monday’s open versus the ~$23 post-split equivalent
- Whether the ADS holds above $20
- NYSE compliance notices
Forecast: Expect a volatile first week. A hold above ~$21 (post-split) would be constructive, while a slide toward ~$18 would suggest the old downtrend has resumed.
Why This Matters: AMTD is the largest ratio on the first day of the calendar, and a template for what a 60-to-1 reset does to a micro-cap.
2. Lufax Holding (LU) | Last Verified ~$0.8682 | The 1-for-10 ADS Reset on October 23
The Chinese Lender’s Second Reset in Three Years Targets Sub-$1 Risk
Lufax will change its ADS ratio from two to 20 ordinary shares around October 23, the same as a one-for-ten reverse ADS split, with ordinary shares unchanged.
| Metric | Value |
|---|---|
| Split Terms | 1-for-10 ADS ratio change (2 → 20 ordinary shares per ADS); effective ~Oct 23; NYSE: LU, HKEX: 6623 |
| Last Verified Price | ~$0.8682 (At close: October 16 at 4:00:02 p.m. EDT) |
| Recent Trend | Weekly closes slid from ~$1.26 to ~$1.04; shares fell ~12.6% in that week |
| Market Cap | ~$0.9B (estimated from ADS count) |
| Post-Split Equivalent | ~$10.40 ($1.04 × 10) |
| Net Income (last year) | About -$1.07B |
| Prior Split | 1-for-4 in December 2023 |
| Volume vs. Average | Not confirmed (older average ~3.6M) |
| Support 1 / 2 / 3 (pre-split) | $1.00 / $0.90 / $0.80 → ~$10.00 / $9.00 / $8.00 post-split |
| Resistance 1 / 2 / 3 (pre-split) | $1.04 / $1.26 / $1.50 → ~$10.40 / $12.60 / $15.00 post-split |
Catalyst & Latest News: StocksToTrade notes that the ADS ratio change is a pricing event, not a fundamental catalyst, and that sub-$1 risk was building before the announcement.
Technicals: Weekly closes slid from $1.26 to $1.04 with an accelerating decline in early October, so $1.00 is the key level on the pre-split chart.
Fundamentals: Lufax is a financial services enabler for small-business owners in China and dual-listed in Hong Kong. It has long traded at a steep discount to book value.
Bull Case: A cleaner ADS price, a deeply discounted valuation and a two-market listing. Bear Case: A prior 1-for-4 in 2023 did not reverse the decline, and the company has no assurance the post-split price will hold.
What to Watch:
- Oct. 23 open versus ~$10 post-split
- NYSE notices
- Any restructuring or capital news
Forecast: A hold above ~$9 post-split would keep the listing risk in check. A break below it would put ~$8 in play.
Why This Matters: LU is the largest company on the calendar, showing that even big names use ratio changes to fix an ADS price.
3. Solowin Holdings (AXG) | Last Verified $1.30 (-20.7%) | A 1-for-200 Reset on a ~$250 Million Company
A Two-Hundred-to-One Split With No Sub-$1 Excuse
Solowin is consolidating its shares 200-to-1 effective October 26, per the calendar, on a stock last verified at $1.30.
| Metric | Value |
|---|---|
| Split Terms | 1-for-200; effective Oct 26 (per calendar) |
| Last Verified Quote | $1.30 (-20.73%); the quote’s date was not shown |
| 52-Week Range | $1.26 – $4.75 |
| Market Cap | ~$253M |
| Post-Split Equivalent | ~$260 ($1.30 × 200) |
| Volume vs. Average | 898,314 vs. ~236,330 |
| P/E / Dividend | Negative (EPS about -$0.11) / None |
| Business | Hong Kong fintech: AX COIN stablecoin issuance, securities brokerage, asset management |
| Support 1 / 2 / 3 (pre-split) | $1.26 / $1.00 / $0.80 → ~$252 / $200 / $160 post-split |
| Resistance 1 / 2 / 3 (pre-split) | $1.64 / $1.67 / $2.00 → ~$328 / $334 / $400 post-split |
Catalyst & Latest News: I could not find a company statement explaining the ratio. A stock above $1 does not need a split for bid-price compliance, so the motive is unclear.
Technicals: Yahoo’s quote shows a 20.7% drop on volume nearly four times average, and the stock sat at its 52-week low.
Fundamentals: Ortex lists ~157.6M shares outstanding and a 33% free float. Benzinga shows the stock at $2.85 on August 6, so the decline since then is steep.
Bull Case: A stablecoin-linked business at a sharply lower valuation. Bear Case: An unexplained 200-to-1 split, a decline of more than 50% from the $2.85 seen on August 6 (if the $1.30 quote is current) and a post-split float of under one million shares.
What to Watch:
- The issuer’s own filing explaining the ratio
- Liquidity after the split
- Whether the post-split price holds above ~$200
Forecast: Thin post-split floats are prone to wild swings. A close above ~$250 would calm the setup, while a break of ~$200 would suggest the market is pricing in further declines.
Why This Matters: AXG is the calendar’s biggest-cap 200-to-1 split, and not every reverse split is a bid-price cure.
4. Capstone Holding (CAPS) | Last Verified ~$0.0870 (-10.12%) | 27.5 Million Shares Become 918,000 on Monday
A Building-Products Distributor Triples Its Share Count, Then Consolidates 30-to-1
Capstone will implement a 1-for-30 reverse split effective at the open on October 19, cutting shares from about 27.54 million to about 917,898.
| Metric | Value |
|---|---|
| Split Terms | 1-for-30; effective at the open Oct 19; new CUSIP 14068E307 |
| Last Verified Price | ~$0.0870 |
| Share Count | ~27.54M (Oct 8) → ~917,898 post-split; ~9.1M earlier in 2026 |
| Market Cap | ~$4.4M (older estimate) |
| Post-Split Equivalent | ~$19 on the March price (stale) |
| FY2026 Outlook | Revenue +54%, gross profit +73%, EBITDA ~$0.9M → ~$3.8M |
| Volume vs. Average | Not confirmed |
| Support 1 / 2 / 3 (post-split, indicative) | ~$19.00 / $15.00 / $12.00 |
| Resistance 1 / 2 / 3 (post-split, indicative) | ~$21.00 / $25.00 / $30.00 |
Catalyst & Latest News: Capstone’s earlier FAQ called a reverse split a contingency if the stock stayed under the $1.00 minimum bid. Its CEO cut his cash salary to $1.
Technicals: Without a verified current price, the levels above are indicative only and anchored to the March price times 30.
Fundamentals: The company added more than $25 million in revenue through acquisitions in 2025, and management says part of reported interest expense is non-cash.
Bull Case: Growth in revenue and EBITDA and a new, tradeable price. Bear Case: A share count that roughly tripled in months and a sub-$1 starting point.
What to Watch:
- Monday’s opening print
- New financing
- Nasdaq compliance letter
Forecast: If the post-split price holds above the high-teens, the Nasdaq issue likely resolves. A slide toward ~$12 would signal renewed dilution pressure.
Why This Matters: CAPS shows that dilution and a reverse split often travel together.
5. GreenPower Motor (GP) | Last Verified $0.3220 (-7.60%) | A Second Reset in 13 Months
The Electric-Bus Maker Rises 38% on Its Own Share Consolidation Plan
GreenPower’s Nasdaq-approved 1-for-5 consolidation takes effect at the open on October 19, cutting shares from 10,503,546 to about 2,100,710.
| Metric | Value |
|---|---|
| Split Terms | 1-for-5; effective at the open Oct 19; Nasdaq: GP |
| Share Count | 10,503,546 → ~2,100,710 (fractions rounded up, no cash) |
| Last Verified Price | $0.3220 |
| Announcement Reaction | +38.4% after the plan was announced |
| Post-Split Equivalent | ~$4.80–$5.60 on spring prices (stale) |
| Prior Split | 1-for-10 in September 2025 |
| Market Cap | Low single-digit millions to ~$10M (not confirmed) |
| Support 1 / 2 / 3 (post-split, indicative) | ~$4.80 / $4.00 / $3.00 |
| Resistance 1 / 2 / 3 (post-split, indicative) | ~$5.60 / $6.50 / $8.00 |
Catalyst & Latest News: The stock jumped 38.4% on the plan to meet the $1 minimum bid. The previous 1-for-10 consolidation took effect in 2025.
Technicals: An earlier Nasdaq equity-deficiency notice shows the company has had listing problems beyond price.
Fundamentals: GreenPower makes electric school buses and commercial vehicles in the U.S. and Canada, and is thinly held by institutions.
Bull Case: A compliant price, a tradeable float and a niche EV business. Bear Case: A second split in just over a year, tiny equity and persistent cash needs.
What to Watch:
- Monday’s open
- Equity-compliance status
- Financing announcements
Forecast: A close above the post-split $5 area would calm the listing questions. A fade toward $3 would point to another round.
Why This Matters: GP is a case study in serial splitting among micro-cap EV names.
6. Revelation Biosciences (REVB) | Last Verified $0.4847 (-35.80%) | The Sixth Reverse Split in Under Four Years
A Cumulative 1-for-1.4 Million: The Most-Split Name on the Calendar
Revelation will implement a 1-for-7 reverse split on the morning of October 20.
| Metric | Value |
|---|---|
| Split Terms | 1-for-7; effective morning of Oct 20; Nasdaq: REVB |
| Prior Splits | 1-for-35 (Feb 2023), 1-for-30 (Jan 2024), 1-for-16 (Jan 2025), 1-for-3 (Jul 2025), 1-for-4 (Jan 2026) |
| Cumulative Factor | About 1-for-1,411,200 across all six splits |
| Last Verified Price | $0.4847 |
| Share Count | Not confirmed (about 1.5M after the July 2025 split) |
| Volume vs. Average | Not confirmed |
| Reference Level | Nasdaq $1.00 minimum bid (pre-split) → $7.00 post-split |
| Support 1 / 2 / 3 (post-split, indicative) | ~$7.00 / $5.00 / $3.50 |
| Resistance 1 / 2 / 3 (post-split, indicative) | ~$9.00 / $12.00 / $15.00 |
Catalyst & Latest News: The company’s 10-K describes the July 2025 and January 2026 splits, and the January split was intended to regain Nasdaq bid compliance.
Technicals: Because no verified current price was available, the levels are reference zones built on the $1.00 Nasdaq threshold times seven.
Fundamentals: A share held since before February 2023 would now represent about one 1.4-millionth of itself, and the warrants listed in January 2025 had an exercise price of $193,200.
Bull Case: A clinical-stage company that keeps its listing. Bear Case: Six splits in under four years is a pattern of repeated dilution and price erosion.
What to Watch:
- Oct. 20 open
- New financing within weeks
- Nasdaq compliance letter
Forecast: History says the post-split bounce fades quickly. A hold above ~$7 would break that pattern.
Why This Matters: REVB is the clearest example of a split that does not fix the underlying problem.
7. Moleculin Biotech (MBRX) | Last Verified $0.2804 (-24.24%) | The Third Reverse Split in 31 Months
20.9 Million Shares Become 1.05 Million as Annamycin Heads Toward a Pivotal Readout
Moleculin’s 1-for-20 reverse split takes effect at 12:01 a.m. ET on October 20, cutting shares from about 20.9 million to about 1.05 million.
| Metric | Value |
|---|---|
| Split Terms | 1-for-20; effective 12:01 a.m. ET Oct 20; cash for fractional shares |
| Prior Splits | 1-for-15 (March 2024), 1-for-25 (December 2025) |
| Last Verified Price | $0.2804 |
| Market Cap | ~$12.7M |
| 52-Week Range | $0.1614 – $15.75 (split-adjusted data) |
| Post-Split Equivalent | ~$13.00 ($0.65 × 20) |
| Analyst View | H.C. Wainwright cut its target to $3 from $22 |
| Volume vs. Average | Not confirmed |
| Support 1 / 2 / 3 (post-split, indicative) | ~$12.80 / $10.00 / $8.00 |
| Resistance 1 / 2 / 3 (post-split, indicative) | ~$14.00 / $18.00 / $24.00 |
Catalyst & Latest News: Shareholders authorized a split up to 1-for-20 at the October 9 annual meeting, and the company filed in July to sell 4.57 million shares and warrants. Interim MIRACLE data showed complete-remission rates three times those of the control.
Technicals: The September price sits near the bottom of a wide post-split-adjusted range, and the levels above are indicative because no October quote was available.
Fundamentals: The lead drug, Annamycin, is in a Phase 2b/3 trial for relapsed or refractory AML, and the company has about 17 employees.
Bull Case: Positive interim data for an AML program and a cleaner share structure. Bear Case: Three splits in 31 months, a $3 target cut from $22 and ongoing equity raises. Its 2024 split was meant to cure a Nasdaq bid-price deficiency.
What to Watch:
- Oct. 20 open
- New share offerings
- MIRACLE trial updates
Forecast: Holding above ~$12.80 post-split would show the market is giving credit for the data. A new offering would likely pressure shares toward $10.
Why This Matters: MBRX shows a biotech with real clinical data still struggling with the mechanics of a listing.
8. Azitra (AZTR) | Price Not Confirmed | NYSE American’s 1-for-10 on October 26
Precision-Dermatology Biotech Cuts Its Share Count From 60.6 Million to 6.06 Million
Azitra’s 1-for-10 reverse split is effective at 12:01 a.m. ET on October 26, after the board approved the ratio on October 14.
| Metric | Value |
|---|---|
| Split Terms | 1-for-10; effective 12:01 a.m. ET Oct 26; NYSE American: AZTR |
| Share Count | ~60.6M → ~6.06M |
| Last Verified Price | 0.0715 |
| Market Cap | 4.333M |
| Volume vs. Average | 2,670,553 vs. 1,523,909 |
| Fractional Shares | Cashed out |
| Support 1 / 2 / 3 (post-split, indicative) | NA |
| Resistance 1 / 2 / 3 (post-split, indicative) | NA |
Catalyst & Latest News: The company said the split adjusts the stock price and share count without changing ownership percentages, apart from fractional shares.
Technicals: I could not verify a recent price for Azitra, so no support or resistance zones are given. Check the live quote and multiply by ten for the theoretical post-split price.
Fundamentals: Azitra is a clinical-stage biopharmaceutical company focused on precision dermatology.
Bull Case: A more tradeable share price and a clinical-stage pipeline. Bear Case: A 10-to-1 split with no stated catalyst and no verified price data.
What to Watch:
- Oct. 26 open
- NYSE American notices
- Any follow-on offering
Forecast: Without a verified price this is a mechanics-only call: expect heavy first-day volatility.
Why This Matters: AZTR is a reminder that on a calendar like this, the first print after the split carries the information.
9. Biodexa Pharmaceuticals (BDRX) | Market Cap ~$2.5 Million | Four Resets in 15 Months
A 1-for-8 ADS Change Caps a Dizzying Chain of Splits
| Metric | Value |
|---|---|
| Split Terms | 1-for-8 ADS split (50 → 400 ordinary shares per ADS); effective ~Oct 26 |
| Prior Resets | 1-for-10 ADS (July 2025); 1-for-5 ADS (April 6, 2026); 1-for-10,000 share consolidation (mid-2026) |
| Market Cap | ~$2.5M (reported around the July 2026 split) |
| Last Verified Price | 0.4561 |
| Financing | £25M share-allotment authority through 2029; $10M offering priced in January 2026 |
| Volume vs. Average | 631,113 vs. 4,974,210 |
| Support 1 / 2 / 3 (post-split, indicative) | NA |
| Resistance 1 / 2 / 3 (post-split, indicative) | NA |
Catalyst & Latest News: The July 2026 shareholder vote also created a deferred share class and kept the ADS count at 1,029,063, and the April change was a one-for-five ADS split.
Technicals: I could not verify a recent price. A holder of 1,000 ADSs before the October change ends up with 125 after it.
Fundamentals: Biodexa is a clinical-stage company developing gastrointestinal-cancer treatments, with roughly 373 billion ordinary shares before its mid-2026 consolidation.
Bull Case: A pipeline in oncology and a financing toolkit. Bear Case: Four resets in 15 months and a market value of a few million dollars.
What to Watch:
- The exchange mechanics at JPMorgan, the depositary bank
- New offerings
- Nasdaq bid-price status
Forecast: A fifth reset in 2027 is a real possibility if past patterns hold.
Why This Matters: BDRX is the extreme end of serial consolidations among foreign-listed biotechs.
10. Odyssey Marine Exploration (OMEX) | Reference ~$1.10 Pre-Split | Reverse Split Before the AOM Merger
58.6 Million Shares Become 2.3 Million Ahead of a Deep-Sea Mining Merger
| Metric | Value |
|---|---|
| Split Terms | 1-for-25; effective Oct 28; trades split-adjusted at the Oct 29 open; record date Oct 26 |
| Share Count | ~58.6M → ~2.3M (before the merger share issuance) |
| Merger | American Ocean Minerals (AOM); S-4 declared effective Oct 15; exchange ratio 4.5017 → 0.1801 post-split |
| Reference Value | $27.50 per post-split share used in a stake purchase (~$1.10 pre-split) |
| Nasdaq Deficiency | Notice July 21; cure deadline Jan 19, 2027 |
| Last Verified Price | 0.6400 |
| Support 1 / 2 / 3 (post-split, indicative) | ~$25.00 / $22.50 / $20.00 |
| Resistance 1 / 2 / 3 (post-split, indicative) | ~$27.50 / $30.00 / $35.00 |
Catalyst & Latest News: The company filed its 8-K announcing the split date after the S-4 went effective, and Nasdaq gave it 180 days to regain the $1.00 bid.
Technicals: The levels above are indicative and anchored on the $27.50 reference value.
Fundamentals: Pro forma combined weighted shares are about 36.8 million after the split, so legacy holders are heavily diluted by the merger.
Bull Case: Compliance restored ahead of the merger, and a new asset base. Bear Case: Heavy dilution, a pending merger that must still close and no verified live price.
What to Watch:
- The Oct. 29 split-adjusted open
- Merger closing date
- Nasdaq compliance letter
Forecast: A post-split price at or above ~$25 supports the merger’s valuation. A price in the teens would raise doubts.
Why This Matters: OMEX shows a reverse split as one step in a transformation, not a standalone event.
Reverse Stock Splits: Sector Sentiment Snapshot and Forecast
Healthcare and biotech dominate the list, with Moleculin, Revelation, Azitra and Biodexa all consolidating. Foreign issuers use ADS ratio changes, including AMTD, Lufax and Biodexa, to meet exchange rules without touching ordinary shares. Micro-cap industrials and EV names such as GreenPower and Capstone round it out. The pattern across nearly all of them: a split fixes the price, not the cash needs, so follow-on offerings often arrive within weeks. With the 10-year yield above 5%, financing is expensive, which raises the odds of dilution after the split. Our forecast: expect sharp first-day swings and, for most names, fading bounces within a month.
At a Glance: Upcoming Reverse Stock Splits (Oct 19–29, 2026)
| # | Ticker | Ratio | Effective Date | Last Verified Price | Key Fact |
|---|---|---|---|---|---|
| 1 | AMTD | 1-for-60 (ADS) | Oct 19 | $0.4979 | NYSE compliance; ~$23 post-split |
| 2 | LU | 1-for-10 (ADS) | Oct 23 | $0.8682 | Second reset since 2023 |
| 3 | AXG | 1-for-200 | Oct 26 | $0.0925 | ~$253M market cap |
| 4 | CAPS | 1-for-30 | Oct 19 | $0.0870 | 27.5M → ~918K shares |
| 5 | GP | 1-for-5 | Oct 19 | $0.3220 | Second split in 13 months |
| 6 | REVB | 1-for-7 | Oct 20 | $0.4847 | Sixth reverse split |
| 7 | MBRX | 1-for-20 | Oct 20 | $0.2804 | Third split in 31 months |
| 8 | AZTR | 1-for-10 | Oct 26 | $0.0715 | 60.6M → 6.06M shares |
| 9 | BDRX | 1-for-8 (ADS) | Oct 26 | $0.4561 | Fourth reset in 15 months |
| 10 | OMEX | 1-for-25 | Oct 28/29 | $0.6400 | AOM merger |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and micro-cap, clinical-stage biotech and other stocks undergoing reverse splits carry elevated risk, including delisting and heavy dilution. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change. Several prices are labeled “last verified” with a date, are stale, or are unavailable, and “post-split equivalent” figures are theoretical. Split dates and ratios may change if issuers or exchanges amend their notices. Support and resistance levels are analytical reference zones, not guaranteed price targets. Always complete independent due diligence prior to executing equity trades.
About The Author
